- against feline panleucopenia to prevent mortality and clinical signs. - against leukaemia to prevent persistent viraemia and clinical signs of the related disease.

Onset of immunity:

- Rhinotracheitis, calicivirus and panleucopenia component: 1 week after primary vaccination course.

- Feline Leukaemia component: 2 weeks after primary vaccination course.

Duration of immunity:

- Rhinotracheitis, calicivirus and panleucopenia component: 1 year after the primary vaccination course and 3 years after the last re-vaccination. - Feline leukaemia component: 1 year after the last re-vaccination.

Dose to be administered and administration route

Subcutaneous route.

Reconstitute gently the vaccine in order to obtain a uniform suspension with limited foam formation.

Visual appearance after reconstitution: clear slightly yellow suspension with presence of cell debris in suspension.

After reconstitution of the lyophilisate with 0.5 ml or 1 ml of the solvent

(depending on the presentation chosen), inject one dose of vaccine according to the following vaccination schedule:

Primary vaccination course:

- first injection: from 8 weeks of age, - second injection: 3 to 4 weeks later.

Where high levels of maternal antibodies against rhinotracheitis, calicivirosis or panleucopenia components are expected to be present (e.g. in kittens of 9 to 12 weeks of age born from queens which were vaccinated before pregnancy and/or with known or suspected previous exposure to the pathogen(s)), the primary vaccination course should be delayed until 12 weeks of age.

Revaccination:

- the first revaccination must be carried out one year after the primary vaccination course,

Subsequent revaccinations:

- Feline leukaemia component: every year.

- Rhinotracheitis, calicivirosis and panleucopenia components: at intervals of up to three years.

Adverse reactions

Cats:

Common

(1 to 10 animals / 100 animals treated):

Apathy, anorexia, and hyperthermia¹. Injection site reactions (pain, itching, oedema) ².

Uncommon

(1 to 10 animals / 1 000 animals treated):

Hypersensitivity reaction³.

Very rare

(<1 animal / 10 000 animals treated, including isolated reports):

Emesis⁴.

¹ lasting usually for 1 or 2 days.

² slight pain at palpation, itching or limited oedema disappearing within 1 or 2 weeks at most.

³ may require appropriate symptomatic treatment.

⁴ mostly within 24 to 48 hours.

Reporting adverse events is important. It allows continuous safety monitoring of a veterinary medicinal product. Reports should be sent, preferably via a veterinarian, to either the marketing authorisation holder, or its local representative, or the national competent authority via the national reporting system. See section “Contact details” of the package leaflet.